drugset / Trial / NCT02886884
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
Phase 1/2
Completed
16 enrolled
Joshua M Hare
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction.
Timeline
- Start
- 2017-10-20
- Primary completion
- 2019-08-26
- Completion
- 2020-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic Mesenchymal Human Stem Cells | Cell therapy | 20 cells | Intravenous |
| Subject | Allogeneic Mesenchymal Human Stem Cells | Cell therapy | 100 cells | Intravenous |